drug_type
RELEVANT_DRUG
intervention_type
cellular therapy (autologous T-cell therapy)
drug_description
Autologous adoptive T-cell therapy consisting of patient-derived T cells expanded ex vivo to recognize HPV-16 E6/E7 peptides presented by HLA-A*0201 on tumor cells, inducing TCR-mediated cytotoxic killing; administered IV at 5×10^9 or 1.5×10^10 cells per infusion for up to 4 cycles.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
TCR SELECTED T CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells selected and expanded ex vivo for specificity to HPV-16 E6/E7. After infusion, their native TCRs recognize E6/E7 peptides presented by HLA-A*0201 on tumor cells, leading to MHC class I-restricted cytotoxic killing and cytokine-mediated anti-tumor activity.
drug_name
HPV-T
nct_id_drug_ref
NCT05895370